Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal

Lendínez-Cano, Guillermo; Vilches-Arenas, Ángel; Congregado-Ruíz, Belen; Medina-López, Rafael

doi:10.1007/s00345-024-04972-9

World J Urol

2024

DOI: 10.1007/s00345-024-04972-9

|View full text |Cite

Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal

Guillermo Lendínez-Cano,

Ángel Vilches-Arenas,

Belen Congregado-Ruíz

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Letter to the editor for the article “Patient's self‑reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal”

Huang,

Wang,

Yang

et al. 2024

World J Urol

View full text Add to dashboard Cite

Letter to the editor for the article “Patient's self‑reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal”

Huang,

Wang,

Yang

et al. 2024

World J Urol

View full text Add to dashboard Cite

Description of Baseline Quality of Life in Patients Diagnosed with Metastatic Renal Cell Carcinoma

Lendínez-Cano,

Congregado Ruíz,

Gómez Luque

et al. 2024

Urol Int

View full text Add to dashboard Cite

Introduction: Renal cancer (RC) is not typically symptomatic until it reaches a considerable size and an advanced stage [World J Oncol. 2020;11(3):79–87]. The 5-year survival rate for metastatic renal cancer (mRC) is estimated at 13% [CA Cancer J Clin. 2021;71(1):7–33]. Health-related quality of life (HRQoL), obtained as patient-reported outcomes (PRO), reflects the patient’s subjective perception of the disease and treatment impact on their normal activity and well-being [Lancet Oncol. 2016;17(11):e510–4]. Measuring HRQoL can facilitate doctor-patient communication, aid in decision-making, and improve clinical outcomes [Eur Urol Focus. 2020;6(1):26–30]. We will analyse the baseline quality of life of patients diagnosed with mRC, who are candidates for systemic treatment, in our setting, as measured by responses to the NCCN-FKSI 19 questionnaire. Methods: We analysed 78 consecutive patients diagnosed and treated for mRC from September 2012 to September 2019. We described the baseline questionnaire responses of our patients before initiating systemic treatment and analysed their responses. Results: Over 60% of the patients reported some degree of lack of energy or fatigue, 60.8% were very or extremely worried about their disease worsening, and 47.9% had some issues related to rest. Additionally, 26.8% of the patients were not at all satisfied with their quality of life at that time. Conclusions: Patients diagnosed with mRC exhibit deterioration in their quality of life, mostly showing asthenia and concern about their disease. The quality of life of “real-life patients” seems to be worse than that of those included in clinical trials.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal

Cited by 2 publications

References 21 publications

Letter to the editor for the article “Patient's self‑reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal”

Letter to the editor for the article “Patient's self‑reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal”

Description of Baseline Quality of Life in Patients Diagnosed with Metastatic Renal Cell Carcinoma

Contact Info

Product

Resources

About